innosupps glp 1 Inno Supps 3 Bottles of Night Shred™

Peptides (2019) 114:449

These drugs that are FDA-approved for the treatment of diabetes have emerged as a promising new tool in the fight against obesity

Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease

Yet cash-pay barriers keep real-world penetration below 200,000 patients so far, implying enormous headroom once biosimilar pricing compresses

Novo Nordisk obtained marketing approval for Victoza (liraglutide) in 2010 and released it as a non-reimbursable treatment in 2012